myofascial pain syndrome
Conditions
Interventions
None listed
Sponsors
Shinshu University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Inpatients aged 20 to 85 who have been diagnosed with advanced cancer (2) Subjects whose palliative care team is intervening (3) Subjects taking opioids (4) Eastern Cooperative Oncology Group Performance Status (ECOG-PS) 2-4 (5) Subjects diagnosed with myofascial pain syndrome that meets River's diagnostic criteria (6) Subjects who have the pain of 4/10 or higher on the Numerical Rating Scale (NRS) in the affected area of myofascial pain syndrome (7) Subjects whose cause of myofascial pain syndrome is determined to be bed rest for 1 week or longer (8) Subjects who can visualize the muscle layer of the painful area of myofascial pain syndrome using a portable ultrasound device (9) Individuals who are clear-minded and have the ability to make decisions (10) Subjects were judged to be able to keep quiet during the procedure
Exclusion criteria
Exclusion criteria: (1) Subjects taking anticoagulants or antiplatelet drugs (2) Subjects who are suggested to be prone to bleeding (3) Subjects with severe cytopenia (4) Those who are suggested to be susceptible to infection (5) Subjects with skin abnormalities such as redness, swelling, and edema at painful areas suspected of MPS (6) Subjects with chronic heart failure (7) Subjects with serious renal impairment (8) Subjects with severe liver disorder (9) Subjects who are allergic to local anesthetics (10) Subjects whose cause of the pain may be other than MPS due to bed rest (11) Body Mass Index (BMI) of 35 or more, or those who have difficulty in visualizing the muscle layer of the MPS pain site with a portable ultrasound device (12) Subjects who cannot keep quiet during the procedure (13) A person judged to have no decision-making capacity (14) Others who are judged to be inappropriate as subjects by the principal investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the difference in pain (NRS) on day 8 compared to pre-block | — |
Secondary
| Measure | Time frame |
|---|---|
| (1) Difference in pain (NRS) after block on day 1 compared to pain before block on day 1 (2) Difference in pain (NRS) before block on day 4 compared to pain before block on day 1 (3) Difference in pain (NRS) after block on day 4 compared to pain before block on day 1 (4) Difference in opioid dose (oral morphine equivalent) before block on day 1 and on day 8 (5) Frequency of adverse events | — |
Countries
Japan
Contacts
Public ContactKenji Yamamoto
Shinshu University Hospital Palliative care center
Outcome results
None listed